Pages that link to "Q41745295"

The following pages link to Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. (Q41745295):

Displaying 41 items.

• Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine (Q28316118) (← links)
• Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors (Q28316336) (← links)
• Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs (Q28321397) (← links)
• Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase (Q28323740) (← links)
• Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro (Q28333682) (← links)
• Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine (Q28343184) (← links)
• pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo (Q28368048) (← links)
• Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs (Q28378322) (← links)
• Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents (Q28378547) (← links)
• Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. (Q28378727) (← links)
• Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine (Q28378983) (← links)
• An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine (Q28379270) (← links)
• Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians (Q31975873) (← links)
• Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection (Q33393724) (← links)
• Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients (Q33694387) (← links)
• Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group (Q33749177) (← links)
• Evaluation of drug resistance in HIV infection (Q34805974) (← links)
• Emergence of Mutant HIV Reverse Transcriptase Conferring Resistance to AZT (Q35174378) (← links)
• Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. (Q35272996) (← links)
• Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay (Q35834444) (← links)
• Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients (Q36024504) (← links)
• Antiviral therapy: current concepts and practices (Q36070394) (← links)
• The clinical significance of drug-resistance mutants of human immunodeficiency virus (Q36158108) (← links)
• Intravirion reverse transcripts in the peripheral blood plasma on human immunodeficiency virus type 1-infected individuals (Q36637426) (← links)
• In vitro evaluation of experimental agents for anti-HIV activity (Q39989119) (← links)
• Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment (Q40006857) (← links)
• Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. (Q40284727) (← links)
• HIV-1 Drug Resistance: Molecular Pathogenesis and Laboratory Monitoring (Q40393212) (← links)
• Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection (Q40934415) (← links)
• Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. (Q41381139) (← links)
• Chemotherapeutic Options in HIV Infection (Q41505879) (← links)
• Clinical significance and characterization of AZT-resistant strains of HIV-1. (Q41861303) (← links)
• Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. (Q42276100) (← links)
• Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs (Q44355582) (← links)
• The existence of human immunodeficiency virus resistance to nucleoside-analog drugs has not been shown (Q44365601) (← links)
• Reversion from zidovudine resistance to sensitivity on cessation of treatment (Q44379139) (← links)
• Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment (Q45765110) (← links)
• Development and significance of zidovudine resistance in children infected with human immunodeficiency virus (Q45779905) (← links)
• Effect of resistance on combination chemotherapy for human immunodeficiency virus infection (Q45786780) (← links)
• The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population (Q58737239) (← links)
• Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients (Q72655844) (← links)